• Publications
  • Influence
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
TLDR
The revised guidelines are focused primarily on the diagnosis and treatment of patients with sporadic medullary thyroid carcinoma (MTC) and hereditary MTC and developed 67 evidence-based recommendations to assist clinicians in the care of Patients with MTC. Expand
Guidelines for diagnosis and therapy of MEN type 1 and type 2.
TLDR
The specific RET codon mutation correlates with the MEN2 syndromic variant, the age of onset of M TC, and the aggressiveness of MTC; consequently, that mutation should guide major management decisions, such as whether and when to perform thyroidectomy. Expand
Medullary thyroid cancer: management guidelines of the American Thyroid Association.
TLDR
Clinical topics addressed in this scholarly dialog included initial diagnosis and therapy of preclinical disease, management of persistent or recurrent MTC, long-term follow-up and management (including the frequency of follow- up and imaging), and directions for future research. Expand
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
TLDR
Evidence is presented that sequence changes within the coding region of the RET proto-oncogene, a putative transmembrane tyrosine kinase, may be responsible for the development of neoplasia in these inherited disorders. Expand
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
TLDR
Vandetanib demonstrated therapeutic efficacy in a phase III trial of patients with advanced MTC, and met its primary objective of PFS prolongation with vandETanib versus placebo. Expand
Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.
TLDR
Department of Medicine, Columbia University College of Physicians and Surgeons (J.P.B., S.J.N.), Boston, Massachusetts 02114; Department of Surgery, Duke University Medical Center (S.A.W.), Durham, North Carolina 27710. Expand
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
TLDR
It is demonstrated that vandetanib may provide an effective therapeutic option in patients with advanced hereditary MTC, a rare disease for which there has been no effective therapy. Expand
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
TLDR
How recent discoveries have enhanced the understanding of the molecular basis of these diseases and led to improvements in the diagnosis and management of affected patients is summarized. Expand
The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations.
TLDR
An increasing age at diagnosis and greater detection of smaller-sized intrathyroidal PTCs are found and Sharply rising percentages of the follicular variant histology and RAS mutations after 2000 suggest new and more recent etiologic factors. Expand
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
TLDR
The specific RET codon mutation correlates with the MEN2 syndromic variant, the age of onset of M TC, and the aggressiveness of MTC; consequently, that mutation should guide major management decisions, such as whether and when to perform thyroidectomy. Expand
...
1
2
3
4
5
...